Novartis Ag (NVS)
$90.94 0.03 (0.03%)
19:00 EDT NVS Stock Quote Delayed 30 Minutes
Previous Close $90.94
Market Cap 211.96B
PE Ratio 26.67
Volume (Avg. Vol.) 2.28M
Day's Range 90.30 - 91.86
52-Week Range 69.18 - 99.84
Dividend & Yield 2.98 (3.27%)
NVS Stock Predictions, Articles, and Novartis Ag News
- From InvestorPlace
- From the Web
Although it’s one of the major pharmaceuticals, Novartis didn’t directly jump into the vaccine race. That might have been the best move for Novartis stock.
As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.
There is ridiculously big upside potential for Chinese biotech stocks in the next decade. The spread of the pandemic has only strengthened the case.
These blue-chip names are stocks to sell now as the coronavirus continues its rapid spread around the world.
Tesla hit 200,000 pre-orders and there was a bevy of M&A to report. Here's what happened in the stock market today.
The Medicines Company (MDCO) news for Monday about a $9.70 billion deal with Novartis (NVS) has MDCO stock heading higher.
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Of course, the medical opportunity is massive, but Tilray competitor, Canopy Growth (NYSE:CGC), has been aggressively pursuing a multi-pronged approach that inherently diversifies the future revenue streams. CGC’s vision for THC as an ingredient in an array of consumer products separates them from an increasingly crowded industry.
Roku, Autodesk, Splunk and Novartis are our top stock trades on Friday. Going into the long weekend, see why we picked them for next week.
Forget the volatile marijuana stocks. Their partners could be a better and safer investment for most investors. Here are 3 that stand to benefit from the rise of legal cannabis use.
After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5 percent for the day. However, that optimism has faded rather quickly, and TLRY stock has not been able to capitalize on that momentum.
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.
Altria Group Inc (NYSE:MO) was the latest in a frenzied string of M&A and partnerships in the cannabis sector. Marijuana stocks have been the target of billion-dollar investments, and the $102 billion market cap company and owner of veteran cigarette brands Marlboro, Parliament, and Virginia Slims, last month that it was investing approximately $1.8 billion in Canadian-based Cronos Group Inc (NASDAQ:CRON), which is listed both on the TSX as well as the NASDAQ.
From Seeking Alpha
Gainers: Arrowhead Pharmaceuticals (NASDAQ:ARWR) +47%.Eastman Kodak (NYSE:KODK) +39%.Myomo (NYSEMKT:MYO) +35%.Inovio Pharmaceuticals (NASDAQ:INO) +27%.Renren (NYSE:RENN) +25%.AMC Networks (NASDAQ:AMCX) +22%.Pacific Ethanol (NASDAQ:PEIX) +22%.Histogen (NASDAQ:HSTO) +21%.Heat Biologics (NASDAQ:HTBX) +16%.Ossen Innovation (NASDAQ:OSN) +16%.Losers: Novus Therapeutics (NASDAQ:NVUS) -17%.ADT (NYSE:ADT) -13%.American Axle & Manufacturing (NYSE:AXL) -12%.Forterra (NASDAQ:FRTA) -10%.8i Enterprises Acquisition (JFK) -10%.Francesca's (NASDAQ:FRAN) -10%.Grupo Supervielle (NYSE:SUPV) -9%.89bio (NASDAQ:ETNB) -9%.Jounce Therapeutics (NASDAQ:JNCE) -9%.Empresa Distribuidora (NYSE:EDN) -6%.
Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th
From Heat Biologics, Inc.
DURHAM, NC / ACCESSWIRE / September 9, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, will participate on a virtual panel, entitled, "New Approaches to COVID-19: Hidden
Navellier RatingsPowered by Portfolio Grader